Tiziana Life Sciences is trading at $1.03, up 5.05% in pre-market, alongside recent trial news; available reporting does not establish that the news drove the gain.
- On September 28, the company announced that the first three participants received their first doses in its Phase 2a BANYAN ALS trial of intranasal foralumab.
- The trial is planned to enroll 44 people.
- No separate September 29 company catalyst or trading-volume confirmation was found.